Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

被引：0
|
作者：
E Zulato
F Bergamo
A De Paoli
G Griguolo
G Esposito
G L De Salvo
C Mescoli
M Rugge
M Nardin
L Di Grazia
S Lonardi
S Indraccolo
V Zagonel
机构：
[1] Immunology and Molecular Oncology Unit,Department of Medicine
[2] Istituto Oncologico Veneto-IRCCS,undefined
[3] Medical Oncology 1 Unit,undefined
[4] Istituto Oncologico Veneto-IRCCS,undefined
[5] Clinical Trials and Biostatistics Unit,undefined
[6] Istituto Oncologico Veneto-IRCCS,undefined
[7] Pathology and Cytopathology Unit,undefined
[8] University of Padova,undefined
[9] Radiology Unit,undefined
[10] Istituto Oncologico Veneto-IRCCS,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
colorectal cancer; AMPK; angiogenesis; bevacizumab; biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：25 / 32
页数：7
相关论文
共 50 条
  • [1] Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab
    Zulato, E.
    Bergamo, F.
    De Paoli, A.
    Griguolo, G.
    Esposito, G.
    De Salvo, G. L.
    Mescoli, C.
    Rugge, M.
    Nardin, M.
    Di Grazia, L.
    Lonardi, S.
    Indraccolo, S. d
    Zagonel, V.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (01) : 25 - 32
  • [2] High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab
    Garde-Noguera, J.
    Gil-Raga, M.
    Evgenyeva, E.
    Garcia, J. A.
    Llombart-Cussac, A.
    Camps-Herrero, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (04): : 405 - 412
  • [3] High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab
    J. Garde-Noguera
    M. Gil-Raga
    E. Evgenyeva
    J. A. García
    A. Llombart-Cussac
    C. Camps-Herrero
    [J]. Clinical and Translational Oncology, 2016, 18 : 405 - 412
  • [4] Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab
    Passardi, Alessandro
    Azzali, Irene
    Bittoni, Alessandro
    Marisi, Giorgia
    Rebuzzi, Francesca
    Molinari, Chiara
    Bartolini, Giulia
    Matteucci, Laura
    Sullo, Francesco Giulio
    Debonis, Silvia Angela
    Gallio, Chiara
    Monti, Manlio
    Valgiusti, Martina
    Muratore, Margherita
    Rapposelli, Ilario Giovanni
    Ulivi, Paola
    Frassineti, Giovanni Luca
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy
    Svaton, Martin
    Blazek, Jiri
    Krakorova, Gabriela
    Buresova, Marcela
    Teufelova, Zuzana
    Vodicka, Josef
    Hurdalkova, Karolina
    Barinova, Magda
    Pesek, Milos
    [J]. JOURNAL OF CANCER, 2021, 12 (19): : 5753 - 5759
  • [6] Prognostic value of baseline tumour markers in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab and/or cetuximab
    Cierbinski, A.
    Ruessel, J.
    Schmoll, H-J
    [J]. ONKOLOGIE, 2013, 36 : 72 - 72
  • [7] Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab
    Sastre, Javier
    Vidaurreta, Marta
    Gomez, Auxiliadora
    Rivera, Fernando
    Massuti, Bartomeu
    Reboredo Lopez, Margarita
    Abad, Albert
    Gallen, Manuel
    Benavides, Manuel
    Aranda, Enrique
    Diaz Rubio, Eduardo
    [J]. CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 280 - 286
  • [8] Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy
    Svaton, Martin
    Blazek, Jiri
    Krakorova, Gabriela
    Pesek, Milos
    Buresova, Marcela
    Teufelova, Zuzana
    Vodicka, Josef
    Hurdalkova, Karolina
    Barinova, Magda
    Topolcan, Ondrej
    [J]. ANTICANCER RESEARCH, 2021, 41 (04) : 2053 - 2058
  • [9] Bevacizumab plus chemotherapy promising for colorectal cancer
    Lindsey, H
    [J]. LANCET ONCOLOGY, 2003, 4 (03): : 137 - 137
  • [10] The effect of bevacizumab plus chemotherapy on the immunological profile of advanced colorectal cancer patients
    Rovati, B.
    Manzoni, M.
    Bencardino, K.
    Ronzoni, M.
    Mariucci, S.
    Loupakis, F.
    Gattoni, E.
    Villa, E.
    Falcone, A.
    Danova, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345